CagriSema Shows Promising Results in Late-Stage Obesity Trial
A late-stage analysis of Novo's CagriSema among adult women has yielded significant weight loss results, with an average 25% reduction compared to a 3% loss for those given a placebo.
Novo's next-generation obesity drug CagriSema has shown promising results in a late-stage analysis conducted among adult women.
The study revealed that CagriSema caused an average weight loss of 25% among the participants, who were mostly women with obesity or those classified as overweight. This is significantly higher than the 3% weight loss observed in individuals given a placebo. The trial results are based on data collected from approximately 2,300 patients.
CagriSema combines semaglutide, the active ingredient in Wegovy and Ozempic, with cagrilintide, which targets the amylin pathway to regulate hunger and fullness hormones. By leveraging this new mechanism of action, Novo aims to create a treatment that can offer improved weight loss benefits compared to existing GLP-1 drugs.
The Danish pharmaceutical company will continue to conduct further research to confirm its hypotheses based on these post-study analyses. The results are expected to inform the development and potential launch of CagriSema early next year, which could provide Novo with a new revenue stream in the obesity treatment market.
The second analysis of CagriSema's efficacy has yielded promising results in a specific demographic. When women are grouped by their menopausal status, weight loss is significantly higher on the drug compared to those receiving a placebo. The percentage of weight lost at 68 weeks varies depending on the menopause stage: premenopausal women experienced an average weight loss of 26.7%, while perimenopausal and postmenopausal women saw losses of 24.8% and 23.1%, respectively.
These results are consistent with previous findings that CagriSema is effective in reducing abdominal fat, as measured by waist circumference, across all menopause stages. The data suggest that the drug has a positive impact on body composition for women overall.
The latest analysis indicates that women may experience slightly greater weight loss on CagriSema compared to the broader population of obese adults who participated in the phase 3 trial. This is an important consideration as it suggests that the drug's efficacy may be more pronounced in women, a demographic that often struggles with weight gain due to hormonal changes.
Declining estrogen levels during menopause can lead to weight gain and muscle loss, making it challenging for women to maintain their ideal body composition. The findings from this analysis are particularly relevant given these physiological changes, which occur as women transition through different stages of menopause.
The physiological changes that occur during menopause can have significant effects on women's bodies, including weight gain. This is particularly relevant given the large number of women in the US who are 40 and older - over 86 million according to the U.S. Census Bureau.
These women often experience weight gain as they transition through different stages of menopause, making it a critical area for research into investigational products like CagriSema. According to Michelle Skinner Moore, Novo's interim head of clinical development, medical and regulatory affairs, it is essential to explore these treatments across the reproductive lifespan.
Despite initial concerns from investors over previous late-stage trial results, analysts expect significant demand for CagriSema, predicting $11.84 billion in sales specifically for obesity treatment by 2028, according to a consensus estimate compiled by FactSet.
Facts based on reporting originally published by CNBC.
You may republish this story, in full or in part, if you credit Noti Group and link to it (licence CC BY 4.0). Photos are not included.
